Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) fell 5.8% during trading on Tuesday . The company traded as low as $3.27 and last traded at $3.27, with a volume of 147,047 shares traded. The stock had previously closed at $3.47.

A number of research firms have commented on RGLS. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 6th. FBR & Co reaffirmed an “outperform” rating and issued a $9.00 price objective (down previously from $30.00) on shares of Regulus Therapeutics in a research note on Tuesday, June 28th. Wedbush reaffirmed an “outperform” rating and issued a $15.00 price objective (down previously from $35.00) on shares of Regulus Therapeutics in a research note on Tuesday, June 28th. Needham & Company LLC lowered their price objective on shares of Regulus Therapeutics from $25.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, June 28th. Finally, BMO Capital Markets cut shares of Regulus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $16.00 to $4.00 in a research note on Tuesday, June 28th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $10.42.

The firm has a 50-day moving average of $4.64 and a 200-day moving average of $6.06. The stock’s market cap is $169.95 million.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. On average, analysts predict that Regulus Therapeutics Inc. will post ($1.54) EPS for the current year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.